NASDAQ:AGIO - Agios Pharmaceuticals Stock Price, Forecast & News

Agios Pharmaceuticals trades on the NASDAQ under the ticker symbol "AGIO."

Agios Pharmaceuticals Inc (NASDAQ:AGIO) announced its earnings results on Thursday, October, 31st. The biopharmaceutical company reported ($1.81) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($1.85) by $0.04. The biopharmaceutical company earned $26.02 million during the quarter, compared to analyst estimates of $33.13 million. Agios Pharmaceuticals had a negative return on equity of 70.07% and a negative net margin of 356.42%. Agios Pharmaceuticals's revenue for the quarter was up 71.2% compared to the same quarter last year. During the same period last year, the company earned ($1.63) EPS. View Agios Pharmaceuticals' Earnings History.

Agios Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, February 13th 2020. View Earnings Estimates for Agios Pharmaceuticals.

13 equities research analysts have issued 1-year price objectives for Agios Pharmaceuticals' stock. Their forecasts range from $49.00 to $80.00. On average, they anticipate Agios Pharmaceuticals' share price to reach $65.50 in the next twelve months. This suggests a possible upside of 23.1% from the stock's current price. View Analyst Price Targets for Agios Pharmaceuticals.

13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Agios Pharmaceuticals in the last year. There are currently 2 hold ratings and 11 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Agios Pharmaceuticals.

Headlines about AGIO stock have been trending very positive recently, InfoTrie Sentiment reports. The research firm identifies positive and negative news coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Agios Pharmaceuticals earned a media sentiment score of 3.3 on InfoTrie's scale. They also assigned news stories about the biopharmaceutical company a news buzz of 2.0 out of 10, meaning that recent news coverage is very unlikely to have an impact on the company's share price in the next few days. View News Stories for Agios Pharmaceuticals.

Some companies that are related to Agios Pharmaceuticals include Elanco Animal Health (ELAN), Mylan (MYL), Teva Pharmaceutical Industries (TEVA), Bausch Health Companies (BHC), Beigene (BGNE), Ono Pharmaceutical (OPHLF), Catalent (CTLT), Sarepta Therapeutics (SRPT), Ionis Pharmaceuticals (IONS), Jazz Pharmaceuticals (JAZZ), Perrigo (PRGO), Dr.Reddy's Laboratories (RDY), Amarin (AMRN), Horizon Therapeutics (HZNP) and The Medicines (MDCO).

Based on aggregate information from My MarketBeat watchlists, some companies that other Agios Pharmaceuticals investors own include Celgene (CELG), Gilead Sciences (GILD), Alibaba Group (BABA), bluebird bio (BLUE), Intercept Pharmaceuticals (ICPT), Netflix (NFLX), Tesla (TSLA), AbbVie (ABBV), NVIDIA (NVDA) and Micron Technology (MU).

Agios Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Rhenman & Partners Asset Management AB (0.27%), California Public Employees Retirement System (0.20%), W.E. Donoghue & Co. LLC (0.08%), Wealthstreet Investment Advisors LLC (0.06%), Virginia Retirement Systems ET AL (0.04%) and Zurcher Kantonalbank Zurich Cantonalbank (0.01%). Company insiders that own Agios Pharmaceuticals stock include Carman Alenson, Christopher Bowden, Corp /De/ Celgene, David P Schenkein, David Scadden, Jacqualyn A Fouse, John Maraganore, Kaye I Foster-Cheek, Scott Biller and Steven L Hoerter. View Institutional Ownership Trends for Agios Pharmaceuticals.

AGIO stock was sold by a variety of institutional investors in the last quarter, including Rhenman & Partners Asset Management AB and Steward Partners Investment Advisory LLC. Company insiders that have sold Agios Pharmaceuticals company stock in the last year include Carman Alenson, Christopher Bowden, Scott Biller and Steven L Hoerter. View Insider Buying and Selling for Agios Pharmaceuticals.

AGIO stock was purchased by a variety of institutional investors in the last quarter, including W.E. Donoghue & Co. LLC, California Public Employees Retirement System, Virginia Retirement Systems ET AL, Wealthstreet Investment Advisors LLC, NEXT Financial Group Inc and Zurcher Kantonalbank Zurich Cantonalbank . Company insiders that have bought Agios Pharmaceuticals stock in the last two years include Corp /De/ Celgene, David P Schenkein, David Scadden and Jacqualyn A Fouse. View Insider Buying and Selling for Agios Pharmaceuticals.

Shares of AGIO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of AGIO stock can currently be purchased for approximately $53.19.

Agios Pharmaceuticals has a market capitalization of $3.13 billion and generates $94.39 million in revenue each year. The biopharmaceutical company earns $-346,020,000.00 in net income (profit) each year or ($6.03) on an earnings per share basis. Agios Pharmaceuticals employs 482 workers across the globe.View Additional Information About Agios Pharmaceuticals.

The official website for Agios Pharmaceuticals is http://www.agios.com/.

Agios Pharmaceuticals' mailing address is 88 SIDNEY STREET, CAMBRIDGE MA, 02139. The biopharmaceutical company can be reached via phone at 617-649-8600 or via email at [email protected]